Laboratory evaluation of vasoreactivity parameters (asymmetric dimethylarginine, nitric oxide, fibrinogen and high sensitive C-reactive protein) in patients with polycystic ovary syndrome

Accepted 28th April, 2020

ABSTRACT

The present study aimed to evaluate fibrinogen, high sensitivie C reactive protein (hsCRP), asymmetric dimethylarginine (ADMA) and nitric oxide (NO) levels as laboratory parameters of vasoreactivity in patients with polycystic ovary syndrome (PCOS). Thirty patients with PCOS and 30 women with normal ovulating cycles were enrolled in the study. Serum levels of NO, ADMA, fibrinogen, FSH, LH and hsCRP were assessed and compared with the control group. The mean ADMA, fibrinogen and hsCRP levels were found to be significantly higher, and NO concentrations were lower in the patient group. A significant positive correlation was observed between ADMA and NO levels, ADMA and fibrinogen (r=0.838, p<0.001), and ADMA and hsCRP concentrations. Fibrinogen and NO, and NO and hsCRP levels were significantly negatively correlated in the patient group. In the control group, there was a positive correlation between fibrinogen and age, and there was a negative correlation between NO and FSH. The present study found positive relationship between ADMA levels and vasoreactive parameters of patients with PCOS. Women with PCOS have elevated levels of ADMA, fibrinogen and decreased NO that make them candidates for cardiovascular disease. Further studies are required to establish the association of ADMA with vascular reactivity.

Key words: Polycystic ovary syndrome, asymmetric dimethylarginine, high sensitivie C-reactive protein, vasoreactivity.

INTRODUCTION

Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting approximately 8–13% of women of reproductive age (Franks, 1995; Escobar-Morreale, 2018). Although there are different criteria for defining the disorder, more important is the need to clearly define the phenotype of the patient being considered. PCOS phenotypes can generally be categorized into four types: a) phenotype A, demonstrating evidence of hyperandrogenemia (HA), either clinical, such as hirsutism, and/or biochemical, that is, HA, ovulatory dysfunction (OD), often reflected by menstrual dysfunction, and (polycystic ovarian morphology) PCOM; b) phenotype B, which includes HA and OD, but not PCOM; c) phenotype C, including HA and PCOM, but not OD; and d) phenotype D, with OD and PCOM, but not HA. Metabolically, phenotypes A and B (also called “classic PCOS”) behave similarly, with approximately 75 to 85% demonstrating insulin resistance (IR) and some form of metabolic dysfunction. These individuals have an increased risk of glucose intolerance and diabetes. PCOS women with phenotype D do not demonstrate overt evidence of androgen excess, have little evidence of metabolic dysfunction and are at low risk of developing disorders of glucose intolerance. Patients with phenotype C (often referred to as “ovulatory PCOS”) have levels of metabolic dysfunction and risk that are somewhat less than those with the classic forms of PCOS but still measurably higher than those of control subjects or nonhyperandrogenic PCOS women (Murphy et al., 2006;
Lizneva et al., 2016).

Asymmetric dimethylarginine (ADMA) is a novel regulator of nitric oxide (NO) production by inhibiting NO synthesis (Vallance et al., 1992; Sohaei et al., 2019). Recent studies have shown that ADMA has significant effect on systemic vascular resistance (Charitidou et al., 2008). Plasma levels of ADMA apparently enhanced in atherosclerotic process and it was established that ADMA is an independent determinant of intima-media thickness (IMT) (Boger et al., 2005). Elevated levels of ADMA stimulate vasoconstriction and platelet adhesion that facilitate the proatherogenic effect of the molecule (Sohaei et al., 2019; Miyazaki et al., 1999).

Fibrinogen has been considered as an independent risk factor for cardiovascular disease (Nacul et al., 2007). A number of studies have linked higher plasma fibrinogen concentrations with an increased risk of cardiovascular disease (Folsom et al., 1998). Women with PCOS have elevated levels of fibrinogen (Yildiz et al., 2002)

L-arginine derivate, NO, is a potent vasodilator and provides protection against atherogenic states by inhibiting thrombocyte aggregation, smooth muscle proliferation and inflammatory mediator production (Ozgurtas et al., 2008). Hyperinsulinemia and IR lead to decrease in the release of NO and increase in the production of fibrinogen, as both reflect atherosclerosis (Lindahl et al., 1996). Women with PCOS reflect blunted response to NO-dependant vasodilatation as demonstrated in many recent studies (Ozgurtas et al., 2008; Lindahl et al., 1996; Lakhani et al., 2005; Meng, 2019; Krishnaa et al., 2017).

Inflammation and oxidative stress in PCOS condition is also manifested by the increase of high sensitive C reactive protein (hs-CRP), Il-6 and chitotriosidase (CHT). Inflammatory state accompanies another element of PCOS in pathogenesis, which is the disorder in action and release activity of insulin. The growth of insulin level increases the production of androgens through the activity of ovarian theca cells (Szczyzko et al., 2016).

Patients with PCOS exhibit increased vascular IMT and decreased flow mediated dilatation (Franks, 1995). Guzick et al. (1996) stated that women with PCOS have greater carotid IMT than healthy individuals. Recent parameters of vascular reactivity such as ADMA, NO and fibrinogen may provide complementary data on the evaluation of vascular complications of this disorder (Boger et al., 2005). PCOS is associated with low-grade systemic inflammation as evidenced by elevation of multiple markers of inflammation; such as Il-6, ChT, hs-CRP and white blood cell count which also represent endothelial dysfunction and increased oxidative stress (Krishnaa et al., 2017; Szczyzko et al., 2016; Guzick et al., 1996; Talbott et al., 2001).

In this presented study, we aimed to compare fibrinogen, hs-CRP, ADMA and NO levels as laboratory parameters of vasoreactivity in patients with PCOS and healthy women, and to evaluate the possible relationship between these parameters and hormones of patients, in order to predict their possible cardiovascular effects.

**PATIENTS AND METHODS**

Power analysis was performed using the mean values from the study conducted by Rashidi et al. (2016). The minimum sample size was calculated to be 29 patients in each group with 90% power and 5% alpha error. Age and BMI matched 30 patients with non-obese PCOS and 30 non-obese women with normal ovulating cycles were enrolled to this cross-sectional study with a comparison group. Diagnosis of PCOS was based on the revised Rotterdam criteria (PCOS Consensus Workshop 2004). Patients with the following criteria were included; amenorrhea or oligomenorrhea (< 6 cycles for each year), polycystic ovaries on ultrasonographic examination (presence of 12 or more follicles in each ovary measuring 2–9 mm in diameter, and/or increased ovarian volume (>10 ml)) and clinical and/or biochemical evidences of HA. None of participants had been receiving any medication during the last 3 months. Patients with pregnancy, liver or renal dysfunction, smoking, obesity, diabetes mellitus, hypertension, hyperprolactinemia or thyroid disease were excluded. The study was approved by the ethical review committee of Dicle University, Diyarbakir, Turkey. Written informed consent was obtained from all participants.

All the participants were examined by the same physician, and ultrasonographic examination was performed by the same radiologist. BMI was determined as the ratio of weight in kilograms to height in meters (kg/m²).

Blood samples were obtained after 12-h fasting period. Serum NO levels were measured using a colorimetric method based on the Griess reaction, in which nitrite is reacted with sulphanilamide and N-(1-naphthyl) ethylenediamide to produce an azo dye that can be detected at 540 nm. This was carried out after enzymatic reduction of nitrate to nitrite with nitrate reductase. ADMA was measured by high performance liquid chromatography (HPLC) according to the method described by Chen et al. (2010). Fibrinogen concentration was measured in heparinized plasma and hs-CRP in serum using nephelometric method in BN ProSpec (Siemens) analyzer. Biochemical variables were analyzed by photometric method in Siemens Advia 1800 device.

**Statistical analysis**

Statistical calculations were performed using the SPSS for Windows computer program (release 21.0; SPSS Inc., Chicago, IL, USA). Shapiro-Wilk test was used for determining whether variables are normally distributed. Normally distributed variables (age, BMI, FSH and fibrinogen) were analyzed with the student t test. Non-normally distributed variables (LH, LH/FSH ratio, ADMA,
Table 1: Demographic features, metabolic and hormonal parameters of patients and control subjects.

<table>
<thead>
<tr>
<th></th>
<th>Patients (n=30)</th>
<th>Controls (n=30)</th>
<th>Total</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>26.40 ± 4.46</td>
<td>25.70 ± 4.78</td>
<td>26.05 ± 4.60</td>
<td>0.560</td>
</tr>
<tr>
<td>BMI</td>
<td>26.20 ± 3.21</td>
<td>25.66 ± 3.05</td>
<td>25.93 ± 3.12</td>
<td>0.505</td>
</tr>
<tr>
<td>FSH</td>
<td>5.93 ± 1.58</td>
<td>5.98 ± 1.63</td>
<td>5.96 ± 1.59</td>
<td>0.908</td>
</tr>
<tr>
<td>LH</td>
<td>6.80 (2.21 - 32.63)</td>
<td>4.61 (1.60 - 12.30)</td>
<td>5.35 (1.60 - 32.63)</td>
<td>0.005</td>
</tr>
<tr>
<td>LH/FSH Ratio</td>
<td>1.27 (0.39 - 4.73)</td>
<td>0.73 (0.27 - 2.35)</td>
<td>0.89 (0.27 - 4.73)</td>
<td>0.008</td>
</tr>
<tr>
<td>ADMA</td>
<td>1.22 (0.65 - 1.86)</td>
<td>0.52 (0.34 - 0.82)</td>
<td>0.72 (0.34 - 1.86)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>NO</td>
<td>53.55 (33.10 - 63.40)</td>
<td>72.20 (56.60 - 95.20)</td>
<td>59.90 (33.10 - 95.20)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>5.43 ± 0.77</td>
<td>2.63 ± 0.71</td>
<td>4.03 ± 1.59</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HsCRP</td>
<td>13.35 (6.20 - 16.20)</td>
<td>1.85 (1.10 - 6.40)</td>
<td>6.25 (1.10 - 16.20)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are given as mean ± standard deviation or median (minimum - maximum) according normality.

Table 2: Relationship between variables for the patients group.

<table>
<thead>
<tr>
<th></th>
<th>BMI</th>
<th>FSH</th>
<th>LH</th>
<th>LH/FSH Ratio</th>
<th>ADMA</th>
<th>NO</th>
<th>Fibrinogen</th>
<th>HsCRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>r 0.255</td>
<td>0.099</td>
<td>0.194</td>
<td>0.160</td>
<td>-0.157</td>
<td>-0.121</td>
<td>-0.164</td>
<td>-0.251</td>
</tr>
<tr>
<td></td>
<td>p 0.174</td>
<td>0.603</td>
<td>0.304</td>
<td>0.397</td>
<td>0.406</td>
<td>0.523</td>
<td>0.385</td>
<td>0.182</td>
</tr>
<tr>
<td>BMI</td>
<td>r -0.093</td>
<td>-0.210</td>
<td>-0.230</td>
<td>0.045</td>
<td>-0.045</td>
<td>-0.088</td>
<td>0.017</td>
<td></td>
</tr>
<tr>
<td></td>
<td>p 0.627</td>
<td>0.265</td>
<td>0.221</td>
<td>0.813</td>
<td>0.814</td>
<td>0.643</td>
<td>0.930</td>
<td></td>
</tr>
<tr>
<td>FSH</td>
<td>r 0.325</td>
<td>-0.101</td>
<td>-0.086</td>
<td>0.022</td>
<td>0.058</td>
<td>0.045</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p 0.080</td>
<td>0.595</td>
<td>0.652</td>
<td>0.907</td>
<td>0.763</td>
<td>0.815</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LH</td>
<td>r 0.886</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p &lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LH/FSH Ratio</td>
<td>r 0.555</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p 0.771</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADMA</td>
<td>r 0.916</td>
<td></td>
<td></td>
<td></td>
<td>0.838</td>
<td>0.889</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p &lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NO</td>
<td>r 0.783</td>
<td></td>
<td></td>
<td></td>
<td>0.799</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p &lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>r 0.800</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>p &lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

r: Correlation coefficient.

NO, hsCRP) were analyzed with the Mann Whitney U test. Data were expressed as mean ± standard deviation or median (minimum - maximum) according normality. Pearson or Spearman correlation coefficients (depending normality) were calculated to evaluate the relationships between the various parameters studied. A P-value < 0.05 was considered to be statistically significant.

RESULTS

The mean age of patients and control subjects were similar (p=0.560). Patients with PCOS had slightly higher BMI when compared with the control subjects, however this difference did not achieve statistical significance (p=0.505), and there was no significant difference between groups in terms of FSH levels (p=0.908) as shown in Table 1. The LH levels of the patients were significantly higher than the control subjects (p<0.005).

The mean ADMA levels were significantly higher in the patient group than in control group (1.22 vs 0.52, respectively). Plasma concentrations of fibrinogen and hsCRP were significantly higher in patients with PCOS than the control group (p<0.001 for both). As expected, NO concentrations were significantly lower in patient group than patient group (p<0.001).

A significant positive correlation was observed between ADMA and NO levels in the patient group (r=0.916, p<0.001). Also, there was a significant correlation between ADMA and fibrinogen (r=0.838, p<0.001) and, between ADMA and hsCRP concentrations (r=0.889, p<0.001). Fibrinogen and NO, and NO and hsCRP levels were significantly correlated in the patient group (r=0.783 and r=0.799; respectively and p<0.001 for both) (Table 2).
(Figures 1 to 6). In the control group, there was a positive correlation between fibrinogen and age \((r=0.404, p=0.027)\) and there was a negative correlation between NO and FSH \((r=-0.411, p=0.024)\) (Table 3).
Figure 4: Relationship between Fibrinogen and NO for the patients group.

Figure 5: Relationship between HsCRP and NO for the patients group.

Figure 6: Relationship between HsCRP and Fibrinogen for the patients group.
DISCUSSION

PCOS is a complex endocrine disorder which has hormonal and metabolic components. Although hormonal disturbances of PCOS are relatively well-established, discrepancy still exist in the pathogenesis of metabolic component. We determined a positive correlation between ADMA and fibrinogen or hsCRP, and inverse correlation between ADMA and NO in PCOS patients. To the best of our knowledge, this is the first report that examined the relationship of ADMA, fibrinogen and nitric oxide with metabolic and hormonal parameters of nonobese PCOS patients by comparing with nonobese healthy controls.

Endothelial dysfunction is regarded as the initial step in the development of atherosclerotic process (Walch et al., 2008). Hyper insuliniema, hyperlipidemia, HA and obesity, which are frequently observed in patients with PCOS, are well-known risk factors of vascular complications of the syndrome and exert synergistic effect (Ngo et al., 2011). Duration of exposure to HA and hyper insulinemic environment have significant impact on metabolic and hormonal parameters. Some recent reports mentioned that cardiovascular risk factors are evident in women with PCOS even at the 2nd or 3rd decade of life (Talbott et al., 2000; Lakhani et al., 2004). Cibula et al. (2000) reported that PCOS women are under higher risk of cardiovascular events than control subjects before the age of 45 years. However, little difference was observed in risk factors after 45 years. Conversely, Talbott et al. (2004) determined that women with PCOS younger than 45 years and age matched healthy individuals have similar metabolic parameters and carotid intima-media thickness. There was a serious heterogeneity in age distribution and wide range in BMI in patient group in a previous report (Pamuk et al., 2010). Obesity has additional deleterious effects on glucose tolerance and endothelial functions in patients with PCOS (Dunaif et al., 1989). Our study group consisted of relatively young (< 26 years) nonsmoker and non-obese individuals, and we obtained age and BMI matched control group to eliminate the negative effect of age, smoking and obesity on hormonal and metabolic parameters.

Elevated LH concentrations suggest the presence of HA which is a result of increased synthesis and/or decreased excretion of androgen or androgen precursors (Mai et al., 2008). Although HA is regarded as a contributor of endothelial dysfunction, there are controversial results with respect to effects of androgens on vascular functions (Heutling et al., 2008; Dagre et al., 2006). Our results were in line with previous reports that mentioned to higher levels of LH and increased LH/FSH ratio in patients with PCOS when compared to...
healthy controls (Nacul et al., 2007). Additionally, the relationship of LH and FSH with ADMA level was nonsignificant.

A growing number of evidences have linked elevated fibrinogen levels with increased risk of cardiovascular disease (Folsom et al., 1998). Some recent reports indicated that increased fibrinogen level is a marker of endothelial dysfunction (Szczuko et al., 2016; Dereli et al., 2003). Several experimental and epidemiologic studies; both in human and animal models, demonstrated an association between fibrinogen and atherosclerosis-related disorders including hypertension, diabetes mellitus, myocardial infarction and stroke (Ernst and Resch, 1993). As expected, we observed significantly higher levels of fibrinogen in patients with PCOS and significant correlation of fibrinogen with ADMA and NO levels.

Heutling et al. (2008) found significantly elevated levels of hsCRP which was associated with increased risk of CVD. Kopp et al. (2003) demonstrated a decrease in inflammatory markers subsequent to weight loss. Preliminary data suggest that, in the absence of obesity and smoking, elevated hsCRP is likely to be associated with low grade inflammation resulted with endothelial dysfunction and atherosclerosis in patients with PCOS (Mohlig et al., 2004).

Currently available data from experimental studies document that NO regulate blood flow and has multiple endocrinologic and metabolic functions on human physiology, such as ovulation, pubertal maturation, embryogenesis and timing of menopause, as well as potentiating tissue responsiveness to insulin (Walch et al., 2008; Ngo et al., 2011; Tempfer et al., 2001). Decreased NO production by endothelial cells contributes to elevated blood pressure and systemic vascular resistance (Demir et al., 2011). In the study, patients have significantly lower NO levels than control subjects; consistent with recent reports.

ADMA is a competitive antagonist of NO synthesis and proposed to implicate in disorders related with NO dysfunction including DM, chronic kidney disease, congestive heart failure and atherosclerosis (Lowe, 2000). ADMA is considered as an independent marker of cardiovascular morbidity and mortality (Heutling et al., 2008). Charitidou et al. (2008) stated that ADMA has an advantage of predicting atherosclerotic process and development of cardiovascular events which was not attributed to traditional risk factors. However, Pamuk et al. (2010) and Demirel et al. (2007) determined similar levels of ADMA in patients with PCOS and control subjects. Current clinical and experimental data showed that slight increase in ADMA concentrations; particularly those with PCOS, resulted with higher risk of cardiovascular events that make candidates for ischemic vascular diseases (Valkonen et al., 2001).

We failed to demonstrate a correlation between NO and LH levels. Mather et al. determined that HA or hypergonadotrophinemia have no direct influence on NO concentrations (Mather et al., 2000). We observe a close relation between hsCRP and ADMA and, fibrinogen and ADMA. Our results are in agreement with those reported by Heutling et al. (2008) and Krzyzanowska et al. (2004). Also, NO levels were significantly but inversely correlated with ADMA, fibrinogen and hsCRP.

The present study has some limitations. The major limitation was low sample size due to strict exclusion criteria that obese, smoker, old patients or received any medication in last 3 months were not enrolled. Second, more than single point measurement may enhance significance of the results. Third, long term follow-up needed to demonstrate possible cardiac effects of these inflammatory changes. Finally, the effect of medical therapy on these parameters may help better understanding.

## Conclusion

The present study determined higher circulating ADMA and fibrinogen and, lower NO levels which are associated with worse metabolic profile that may reflect endothelial dysfunction in PCOS patients. Although cardiac effects are expected, further studies are required to clarify the data.

## REFERENCES


Ernst E, Resch KL (1993). Fibrinogen as a cardiovascular risk factor: a


Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schll T, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150: 525-32.


Cite this article as: